Literature DB >> 15494410

Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice.

Dominique Helmlinger1, Jacques Bonnet, Jean-Louis Mandel, Yvon Trottier, Didier Devys.   

Abstract

Nine neurodegenerative diseases, including spinocerebellar ataxia type 7 (SCA7), are caused by the expansion of polyglutamine stretches in the respective disease-causing proteins. A hallmark of these diseases is the aggregation of expanded polyglutamine-containing proteins in nuclear inclusions that also accumulate molecular chaperones and components of the ubiquitin-proteasome system. Manipulation of HSP70 and HSP40 chaperone levels has been shown to suppress aggregates in cellular models, prevent neuronal death in Drosophila, and improve to some extent neurological symptoms in mouse models. An important issue in mammals is the relative expression levels of toxic and putative rescuing proteins. Furthermore, overexpression of both HSP70 and its co-factor HSP40/HDJ2 has never been investigated in mice. We decided to address this question in a SCA7 transgenic mouse model that progressively develops retinopathy, similar to SCA7 patients. To co-express HSP70 and HDJ2 with the polyglutamine protein, in the same cell type, at comparable levels and with the same time course, we generated transgenic mice that express the heat shock proteins specifically in rod photoreceptors. While co-expression of HSP70 with its co-factor HDJ2 efficiently suppressed mutant ataxin-7 aggregation in transfected cells, they did not prevent either neuronal toxicity or aggregate formation in SCA7 mice. Furthermore, nuclear inclusions in SCA7 mice were composed of a cleaved mutant ataxin-7 fragment, whereas they contained the full-length protein in transfected cells. We propose that differences in the aggregation process might account for the different effects of chaperone overexpression in cellular and animal models of polyglutamine diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494410     DOI: 10.1074/jbc.M409062200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Heat shock protein 70 (hsp70) as an emerging drug target.

Authors:  Christopher G Evans; Lyra Chang; Jason E Gestwicki
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 2.  Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases.

Authors:  Herman van der Putten; Gregor P Lotz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

3.  cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in Drosophila.

Authors:  Kanae Iijima-Ando; Priscilla Wu; Eric A Drier; Koichi Iijima; Jerry C P Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-11       Impact factor: 11.205

4.  Preventing polyglutamine-induced activation of c-Jun delays neuronal dysfunction in a mouse model of SCA7 retinopathy.

Authors:  Karine Merienne; James Friedman; Masayuki Akimoto; Gretta Abou-Sleymane; Chantal Weber; Anand Swaroop; Yvon Trottier
Journal:  Neurobiol Dis       Date:  2006-12-26       Impact factor: 5.996

Review 5.  Mouse models of triplet repeat diseases.

Authors:  Gillian P Bates; Roman Gonitel
Journal:  Mol Biotechnol       Date:  2006-02       Impact factor: 2.695

Review 6.  Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.

Authors:  Marta Daniela Costa; Patrícia Maciel
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

Review 7.  Electrophysiological Studies Support Utility of Positive Modulators of SK Channels for the Treatment of Spinocerebellar Ataxia Type 2.

Authors:  Polina A Egorova; Ilya B Bezprozvanny
Journal:  Cerebellum       Date:  2022-01-03       Impact factor: 3.648

Review 8.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  Suppression of protein aggregation by chaperone modification of high molecular weight complexes.

Authors:  John Labbadia; Sergey S Novoselov; John S Bett; Andreas Weiss; Paolo Paganetti; Gillian P Bates; Michael E Cheetham
Journal:  Brain       Date:  2012-03-06       Impact factor: 13.501

Review 10.  Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Authors:  Pawel M Switonski; Wojciech J Szlachcic; Agnieszka Gabka; Wlodzimierz J Krzyzosiak; Maciej Figiel
Journal:  Mol Neurobiol       Date:  2012-09-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.